ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS

Glioblastoma (GBM) remains the deadliest of all primary brain tumors with very few effective treatment options. Recently, we reported that high AXL expression is correlated with poor prognosis in GBM patients and demonstrated the therapeutic benefits of targeting AXL, a member of TAM receptor tyrosi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Ghosh, Sadashib, Sadahiro, Hirokazu, Kang, Kyung-Don, Gibson, Justin T, Minata, Mutsuko, Yu, Hai, Shi, Junfeng, Chhipa, Rishi, Chen, Zhihong, Lu, Songjian, Simoni, Yannick, Furuta, Takuya, Sabit, Hemragul, Zhang, Suojun, Bastola, Soniya, Yamaguchi, Shinobu, Alsheikh, Heba Allah, Komarova, Svetlana, Wang, Jun, Kim, Sung-Hak, Hambardzumyan, Dolores, Lu, Xinghua, Newell, Evan W, Dasgupta, Biplab, Nakada, Mitsutoshi, Lee, L James, Nabors, L Burt, A. Norian, Lyse, Nakano, Ichiro
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216174/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.054
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items